ISSN: 2149-2247 | E-ISSN: 2149-2549
Volume : 45 Issue : 1 Year : 2023
Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report [Erciyes Med J]
Erciyes Med J. 2023; 45(1): 101-103 | DOI: 10.14744/etd.2022.21043

Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report

Emel Mutlu, Metin Özkan, Sedat Tarık Fırat, Ramazan Coşar
Department of Medical Oncology, Erciyes University Faculty of Medicine, Kayseri, Türkiye

Background: Palbociclib is a potent cyclin-dependent kinase (CDK) 4/6 inhibitor that impairs cell cycle progression. It has recently been approved for patients with hormone receptor positive metastatic breast cancer.
Case Report: We report the response achieved palbociclib plus fulvestrant therapy in a 68-year-old female breast cancer patient with bone marrow metastasis. She treated with paclitaxel weekly chemotherapy, but no response was obtained. Then, with dose reduction palbociclib 75 mg/day, plus fulvestrant treatment was administered. After 6 cycles, thrombocyto-penia resolved and the palbociclib dose was increased to 125 mg/day. Cytopenia completely resolved after the eight cycle treatments. She is still going on treatment without progression and side effects.
Conclusion: The efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow metastases have not been clarified. However, palbociclib treatment can be given with close follow-up and dose reduction in breast cancer patients with bone marrow metastasis.

Keywords: Bone marrow metastasis, breast cancer, palbociclib, fulvestrant, CDK 4/6 inhibitors.

Emel Mutlu, Metin Özkan, Sedat Tarık Fırat, Ramazan Coşar. Response and Tolerability of Palbociclib Plus Fulvestrant in Breast Cancer Patient with Bone Marrow Metastasis and Cytopenia: A Case Report. Erciyes Med J. 2023; 45(1): 101-103

Corresponding Author: Emel Mutlu, Türkiye
Manuscript Language: English
LookUs & Online Makale